What is the difference between a closed and a functionally closed system?

A fully closed system is never opened to the environment once sterilized. A functionally closed system may be opened briefly under controlled conditions, for example to make a sterile connection, and then returned to a closed state through a validated step such as a tube weld or a sterile connector. Most current autologous processes are functionally closed.

Does closed-system automation apply to allogeneic therapies too?

Yes, though the economics differ. Allogeneic, donor-derived manufacturing can scale up larger batches from a single donor, so automation there targets batch size and consistency. For autologous therapy the goal is parallel scale-out of many single-patient runs, which makes closure and footprint even more decisive.

How much can closing the process reduce cleanroom costs?

The savings come from operating at a lower cleanroom grade. Open manipulation needs Grade A conditions within a Grade B background, while a functionally closed system can run in Grade C and a validated isolator in a Grade D background. That reduces air handling, gowning, monitoring, and construction costs substantially, although exact figures depend on facility design.

Can a single automated platform handle the entire CAR-T workflow?

Integrated platforms such as the CliniMACS Prodigy and the Lonza Cocoon run most of the workflow inside one enclosed device, but few processes are fully hands-off end to end. Incoming apheresis handling, some quality control sampling, and final fill often remain partly manual, and multi-vendor data integration is still maturing.

Closed-System Automation for Autologous Cell Therapies

Highlights in this article

Key Takeaways
Why does autologous manufacturing demand a different playbook?
What does closing the process actually change?
The automated platform landscape
How does closed-system automation reshape facility design?
Where does automation still fall short?
What this means for scale and cost

Closed-system automation moves autologous cell therapy manufacturing out of open biosafety cabinets and into sealed platforms where a patient's cells never contact the room environment. For manufacturers, the payoff is lower contamination risk, reduced cleanroom classification and cost, and more reproducible batches. That matters acutely when every batch serves a single patient and a failed run cannot simply be repeated.


Key Takeaways Autologous therapies produce one batch per patient, so a contamination event or process failure has no backup, placing sterility assurance and reproducibility above raw throughput. Functionally closed systems maintain a sealed sterile boundary, letting manufacturers run critical steps in lower-grade cleanrooms, Grade C for functionally closed setups and Grade D backgrounds for isolators, which cuts facility and monitoring costs. Integrated platforms automate cell isolation, activation, transduction, expansion, and formulation, reducing the manual touchpoints that drive contamination risk and operator-to-operator variability. The economics follow a scale-out logic, many parallel single-patient runs, rather than the scale-up logic of monoclonal antibody production, so footprint, parallelization, and chain of identity dominate facility design. Closing every step remains hard. The interfaces between unit operations, residual manual handling at intake and fill, and end-to-end electronic batch records are the current frontier.

Key Takeaways

Autologous therapies produce one batch per patient, so a contamination event or process failure has no backup, placing sterility assurance and reproducibility above raw throughput.
Functionally closed systems maintain a sealed sterile boundary, letting manufacturers run critical steps in lower-grade cleanrooms, Grade C for functionally closed setups and Grade D backgrounds for isolators, which cuts facility and monitoring costs.
Integrated platforms automate cell isolation, activation, transduction, expansion, and formulation, reducing the manual touchpoints that drive contamination risk and operator-to-operator variability.
The economics follow a scale-out logic, many parallel single-patient runs, rather than the scale-up logic of monoclonal antibody production, so footprint, parallelization, and chain of identity dominate facility design.
Closing every step remains hard. The interfaces between unit operations, residual manual handling at intake and fill, and end-to-end electronic batch records are the current frontier.

Why does autologous manufacturing demand a different playbook?

Autologous cell therapies are made from a patient's own cells and returned to that same patient. All six FDA-approved CAR-T products, Kymriah, Yescarta, Breyanzi, Tecartus, Abecma, and Carvykti, are autologous, and no off-the-shelf allogeneic CAR-T therapy has reached approval as of 2026. That single fact shapes every downstream manufacturing decision. Where a monoclonal antibody process scales up into ever-larger bioreactors to serve thousands of patients from one batch, an autologous process scales out: one batch per patient, run hundreds or thousands of times in parallel.

The batch of one changes the risk calculus entirely. There is no reserve material and no chance to remake a failed lot from the same starting cells, so a single contamination event can cost a patient their therapy. Vein-to-vein times already stretch across weeks, and the leukapheresis material that starts the process varies from patient to patient. Layered on top is chain of identity and chain of custody: the manufacturer must guarantee that a specific patient's cells are tracked unambiguously from collection through infusion. Traditional open, manual processing in biosafety cabinets, where skilled operators are the single greatest source of contamination, does not scale to this model without multiplying cleanroom suites and staff.

What does closing the process actually change?

A closed system maintains a sealed sterile boundary, so materials move through sterile connectors, tube welds, and single-use assemblies without ever exposing the product to the room. Because cell therapies cannot be terminally sterilized, that boundary is the primary defense against contamination, and regulators under EU GMP Annex 1 and current FDA guidance now expect open manipulations to be minimized and explicitly justified in a contamination control strategy.

The consequences are practical and financial. Open manipulation under a biosafety cabinet requires Grade A conditions within a costly Grade B background. A functionally closed system can run in a Grade C background, and a validated isolator can operate within Grade D, which sharply reduces air handling, gowning, environmental monitoring, and construction costs. Closure also lets multiple single-patient batches proceed in parallel within one cleanroom, the parallelization that scale-out demands. The table below summarizes how the three approaches compare.

Dimension	Open manual (biosafety cabinet)	Functionally closed	Fully automated closed
Sterile boundary	None during manipulation	Sealed; opened briefly under control	Sealed; minimal opening
Cleanroom background	Grade B (Grade A in cabinet)	Grade C	Grade D (validated isolator)
Operator touchpoints	High	Reduced	Minimal
Contamination risk	Highest	Lower	Lowest
Throughput model	One process per suite	Parallel batches per room	Parallel automated units
Main tradeoff	Labor and facility cost	Transfer validation	Consumable cost, less flexibility

The automated platform landscape

Automation layers onto closure by executing unit operations with minimal operator intervention. A modern autologous workflow chains together cell isolation and selection, activation, genetic modification, expansion, washing and concentration, and final formulation. Genetic modification is typically viral transduction, which ties this step directly to upstream viral vector manufacturing and the plasmid DNA that serves as its starting material.

Integrated platforms compress several of these steps into one enclosed instrument. Miltenyi's CliniMACS Prodigy and Lonza's Cocoon aim to run most of the workflow inside a single functionally closed device. Modular systems from Cytiva (Sefia and Xuri) and Thermo Fisher (the Gibco CTS line, including Rotea for cell processing and DynaCellect for activation) let manufacturers close and automate individual unit operations and then connect them. Each approach trades flexibility against integration: an all-in-one device simplifies closure but constrains process changes, while a modular chain preserves flexibility at the cost of more interfaces to validate.

How does closed-system automation reshape facility design?

Because a functionally closed process contains the product, the room around it can be simpler and lower grade, and several batches can run side by side in a shared space. This inverts the traditional cleanroom-centric facility. Rather than a large Grade B suite dedicated to one open process at a time, manufacturers build modular, lower-grade production areas with support functions in standard-construction space adjacent to them. The result is a smaller high-grade footprint, faster and cheaper facility buildout, and capacity that grows by adding parallel units rather than enlarging a single line. For a therapy that must serve a growing patient population one batch at a time, that parallelization is the only realistic path to commercial scale.

Where does automation still fall short?

Full closure and full automation are not yet the same thing, and neither is complete. The hardest problems sit at the interfaces: moving material between unit operations, or between an automated device and a fill step, can reintroduce open manipulations unless every transfer is a validated sterile connection. Many workflows still include manual handling at the edges, particularly at incoming leukapheresis and final fill and finish, and each remaining open step must be justified and supported by aseptic process simulations.

Data is the other frontier. An automated instrument generates process data, but stitching those records into an end-to-end electronic batch record, with the chain of identity intact, still involves significant integration work across instruments from different vendors. Cost and flexibility also pull against each other: a closed, automated platform lowers per-batch labor and contamination risk but carries high consumable costs and can be rigid when a process needs to change. These are engineering and integration challenges rather than fundamental barriers, and they are where much of the current vendor competition is focused.

What this means for scale and cost

The strategic case for closed-system automation is that it attacks the three constraints that most limit autologous therapy: contamination risk, labor, and facility cost. By removing operators from the sterile path, it improves reproducibility and comparability between batches, which regulators scrutinize closely for products where every batch is unique. By lowering the required cleanroom grade and enabling parallel runs, it reduces the capital and operating cost that has kept autologous therapies expensive. The therapies that reach broad, commercial-scale delivery will most likely be the ones whose manufacturers solve closure and automation end to end, not just within individual unit operations. For a fuller view of how these pieces fit together, see our overview of manufacturing cell, gene, and mRNA therapies at scale.